The previously touted plan marks a pivot by Trump, who has repeatedly and inaccurately claimed that more Covid-19 testing would lead to more cases

The White House originally billed the deal to obtain tests, which are made by Abbott Laboratories, as a potential game-changer to battle the coronavirus pandemic. But without detailed federal guidance on how to distribute the tests, states and cities remained divided, and some of them stifled, on how to best to use those types of rapid tests and others for the testing technique known as “screening” — which involves routinely testing people whether or not they have symptoms.

Trump appeared to take a different approach to testing in the Rose Garden on Monday, saying that an increase in coronavirus testing efforts and, therefore, an increase in anticipated asymptomatic coronavirus cases among those in low-risk populations “should not cause undue alarm.”

“As we massively increase testing capacity, we will identify more cases in asymptomatic individuals in low-risk populations. This should not cause undue alarm,” Trump said. “The total number of cases is not the full metric of success. Hospitalization capacity and mortality rates are far more instructive metrics. As we do more tests, you’re going to have, automatically, more cases.”

About 100 million tests, the President said, “will be given to states and territories to support efforts to reopen their economies and schools immediately and (as) fast as they can.”

And 50 million tests will go “to protect the most vulnerable communities,” including nursing homes, assisted living facilities, hospice care, historically black colleges and tribal nation colleges.

Adm. Brett Giroir, the Trump administration’s coronavirus testing czar, said that the federal distribution plan will grant governors flexibility on how they deploy the tests, but offered some prioritization guidance, which included implementing coronavirus screening.

“Governors have the flexibility to use these tests as they deem fit, but we strongly encourage governors to utilize them in settings that are uniquely in need of rapid low-tech point of care tests, like opening and keeping open our K-12 schools, supporting critical infrastructure and first responders, responding to outbreaks specifically in certain demographics or locations, and screening or surveillance in congregate settings,” Giroir said.

Speaking with CNN’s Erin Burnett on “OutFront” later Monday, Giroir touted the distribution of the tests as “a real step forward in our testing.”

“This doesn’t happen overnight. This took planning for months to actually get BinaxNOW rapid point-of-care tests,” he said. “The difference between August and now is just that they had to be assembled. The day after the authorization was issued by the FDA, we signed the contract. That doesn’t happen overnight. That’s with weeks of planning to purchase 150 million.”

He added: “So now that the production is up, we’re able to start distributing to the states. This week, 6.5 million to governors to use as they deem fit. Hopefully for schools and other critical infrastructure.”